Management of VEGFR-Targeted TKI for Thyroid Cancer

Recent advances in the development of multitarget tyrosine kinase inhibitors (MTKIs), which mainly target the vascular endothelial growth factor receptor (VEGFR), have improved prognoses and dramatically changed the treatment strategy for advanced thyroid cancer. However, adverse events related to t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tomohiro Enokida, Makoto Tahara
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	thyroid cancer vascular endothelial growth factor tyrosine kinase inhibitor adverse event Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d297a4b93e314faa9394fbab99a5b059
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d297a4b93e314faa9394fbab99a5b059
record_format	dspace
spelling	oai:doaj.org-article:d297a4b93e314faa9394fbab99a5b0592021-11-11T15:34:07ZManagement of VEGFR-Targeted TKI for Thyroid Cancer10.3390/cancers132155362072-6694https://doaj.org/article/d297a4b93e314faa9394fbab99a5b0592021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5536https://doaj.org/toc/2072-6694Recent advances in the development of multitarget tyrosine kinase inhibitors (MTKIs), which mainly target the vascular endothelial growth factor receptor (VEGFR), have improved prognoses and dramatically changed the treatment strategy for advanced thyroid cancer. However, adverse events related to this inhibition can interrupt treatment and sometimes lead to discontinuation. In addition, they can be annoying and potentially jeopardize the subjects’ quality of life, even allowing that the clinical outcome of patients with advanced thyroid cancer remains limited. In this review, we summarize the potential mechanisms underlying these adverse events (hypertension, proteinuria and renal impairment, hemorrhage, fistula formation/gastrointestinal perforation, wound healing, cardiovascular toxicities, hematological toxicity, diarrhea, fatigue, and acute cholecystitis), their characteristics, and actual management. Furthermore, we also discuss the importance of related factors, including alternative treatments that target other pathways, the necessity of subject selection for safer administration, and patient education.Tomohiro EnokidaMakoto TaharaMDPI AGarticlethyroid cancervascular endothelial growth factortyrosine kinase inhibitoradverse eventNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5536, p 5536 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	thyroid cancer vascular endothelial growth factor tyrosine kinase inhibitor adverse event Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	thyroid cancer vascular endothelial growth factor tyrosine kinase inhibitor adverse event Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Tomohiro Enokida Makoto Tahara Management of VEGFR-Targeted TKI for Thyroid Cancer
description	Recent advances in the development of multitarget tyrosine kinase inhibitors (MTKIs), which mainly target the vascular endothelial growth factor receptor (VEGFR), have improved prognoses and dramatically changed the treatment strategy for advanced thyroid cancer. However, adverse events related to this inhibition can interrupt treatment and sometimes lead to discontinuation. In addition, they can be annoying and potentially jeopardize the subjects’ quality of life, even allowing that the clinical outcome of patients with advanced thyroid cancer remains limited. In this review, we summarize the potential mechanisms underlying these adverse events (hypertension, proteinuria and renal impairment, hemorrhage, fistula formation/gastrointestinal perforation, wound healing, cardiovascular toxicities, hematological toxicity, diarrhea, fatigue, and acute cholecystitis), their characteristics, and actual management. Furthermore, we also discuss the importance of related factors, including alternative treatments that target other pathways, the necessity of subject selection for safer administration, and patient education.
format	article
author	Tomohiro Enokida Makoto Tahara
author_facet	Tomohiro Enokida Makoto Tahara
author_sort	Tomohiro Enokida
title	Management of VEGFR-Targeted TKI for Thyroid Cancer
title_short	Management of VEGFR-Targeted TKI for Thyroid Cancer
title_full	Management of VEGFR-Targeted TKI for Thyroid Cancer
title_fullStr	Management of VEGFR-Targeted TKI for Thyroid Cancer
title_full_unstemmed	Management of VEGFR-Targeted TKI for Thyroid Cancer
title_sort	management of vegfr-targeted tki for thyroid cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d297a4b93e314faa9394fbab99a5b059
work_keys_str_mv	AT tomohiroenokida managementofvegfrtargetedtkiforthyroidcancer AT makototahara managementofvegfrtargetedtkiforthyroidcancer
_version_	1718435211669143552

Management of VEGFR-Targeted TKI for Thyroid Cancer

Ejemplares similares